Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Matters Arising
  • Published:

Reply to Guyton, J. R. & Boden, W. E.; Schreiber, S. et al.

The Original Article was published on 05 September 2024

The Original Article was published on 05 September 2024

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ferrell, M. et al. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nat. Med. 30, 424–434 (2024).

    Article  PubMed  CAS  Google Scholar 

  2. Guyton, J. R. & Boden, W. E. Niacin, food intake and cardiovascular effects. Nat. Med., in press (2024).

  3. Schreiber, S., Waetzig, G. H., Laudes, M. & Rosenstiel, P. Cardiovascular safety of vitamin B3 administration. Nat. Med., in press (2024).

  4. Jenkins, D. J. A. et al. Supplemental vitamins and minerals for CVD prevention and treatment. J. Am. Coll. Cardiol. 71, 2570–2584 (2018).

    Article  PubMed  CAS  Google Scholar 

  5. Shibata, K., Shimada, H. & Taguchi, H. Fate of nicotinamide differs due to an intake of nicotinamide. Biosci. Biotechnol. Biochem. 60, 1204–1206 (1996).

    Article  PubMed  CAS  Google Scholar 

  6. Fulgoni, V. L. 3rd, Keast, D. R., Bailey, R. L. & Dwyer, J. Foods, fortificants, and supplements: where do Americans get their nutrients? J. Nutr. 141, 1847–1854 (2011).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Wu, B. J. et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler. Thromb. Vasc. Biol. 30, 968–975 (2010).

    Article  PubMed  CAS  Google Scholar 

  8. Perlzweig, W. A., Rosen, F., Pearson, P. B., Peck, B. J. & Sparks, P. Comparative studies in niacin metabolism. The fate of niacin in man, rat, dog, pig, rabbit, guinea pig, goat, sheep and calf. J. Nutr. 40, 453–469 (1950).

    Article  CAS  Google Scholar 

  9. Felsted, R. L. & Chaykin, S. N1-methylnicotinamide oxidation in a number of mammals. J. Biol. Chem. 242, 1274–1279 (1967).

    Article  PubMed  CAS  Google Scholar 

  10. Yoshimura, N. et al. N-methyl-2-pyridone-5-carboxamide (N-Me-2PY) has potent anti-fibrotic and anti-inflammatory activity in a fibrotic kidney model: is it an old uremic toxin? Clin. Exp. Nephrol. 27, 901–911 (2023).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

All authors participated in the initial writing and subsequent editing and review of this response.

Corresponding author

Correspondence to Stanley L. Hazen.

Ethics declarations

Competing interests

S.L.H. reports being named as a co-inventor on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics. S.L.H. also reports having received royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland Heart Lab, a fully owned subsidiary of Quest Diagnostics, and Procter & Gamble. S.L.H. is a paid consultant for Zehna Therapeutics and Proctor & Gamble, and has received research funding from Zehna Therapeutics, Proctor & Gamble, Pfizer and Roche Diagnostics. W.H.W.T. has served as a consultant for Sequana Medical, Cardiol Therapeutics, Genomics plc, Zehna Therapeutics, WhiteSwell, Boston Scientific, CardiaTec Biosciences, Intellia Therapeutics, Bristol Myers Squibb, Alleviant Medical, Alexion Pharmaceuticals, Salubris Biotherapeutics and BioCardia, and has received honoraria from Springer, Belvoir Media Group and the American Board of Internal Medicine. All other authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, W.H.W., DiDonato, J.A., Allayee, H. et al. Reply to Guyton, J. R. & Boden, W. E.; Schreiber, S. et al.. Nat Med 30, 2448–2449 (2024). https://doi.org/10.1038/s41591-024-03222-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41591-024-03222-0

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing